Hospira Methotrexate 25 mg/mL Injection 500mg/20mL vial

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

methotrexate, Quantity: 25 mg/mL

Disponible depuis:

Hospira Australia Pty Ltd

DCI (Dénomination commune internationale):

Methotrexate

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid

Mode d'administration:

Intrathecal, Intramuscular, Intravenous, Intraarterial

Unités en paquet:

1 x 20 mL vial, Tray of unpacked 20 mL vials

classe:

Medicine Listed (Export Only)

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Methotrexate Injection is an anti-metabolite medicine and immunosuppressant. Methotrexate is used in large doses to treat certain types of cancer, such as breast cancer. In smaller doses it can be used to treat severe psoriasis, when it has not responded to other treatments.

Descriptif du produit:

Visual Identification: A clear, yellow solution, free from visible particulates.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Licence status A

Date de l'autorisation:

2005-12-21